Cirrhosis News and Research RSS Feed - Cirrhosis News and Research

Cirrhosis is a condition in which the liver slowly deteriorates and malfunctions due to chronic injury. Scar tissue replaces healthy liver tissue, partially blocking the flow of blood through the liver. Scarring also impairs the liver’s ability to control infections, remove bacteria and toxins from the blood, process nutrients, hormones and drugs, make proteins that regulate blood clotting and produce bile to help absorb fats—including cholesterol—and fat-soluble vitamins.
Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Low selenium levels linked to liver cancer risk? An interview with Dr David Hughes

Food provides us with a variety of substances we need to maintain life. These substances are essential nutrients and are classified as macronutrients (water, protein, fats, and carbohydrates) and micronutrients (vitamins and minerals). [More]
Hydrothermal DMR results show promise in treatment of type 2 diabetes

Hydrothermal DMR results show promise in treatment of type 2 diabetes

Fractyl Laboratories Inc. (Fractyl) announced today publication of data in the current issue of Diabetes Care from the Company’s first-in-human study of RevitaTM duodenal mucosal resurfacing (Revita DMR). [More]
Increased treatment for HCV in Rhode Island could help eradicate disease by 2030

Increased treatment for HCV in Rhode Island could help eradicate disease by 2030

A new Brown University study projects that increasing the number of Rhode Islanders treated every year for hepatitis C virus infection (HCV) to about 2,000 by 2020 would reduce cases by 90 percent and prevent more than 70 percent of expected liver-related deaths in the state by 2030. [More]
Sleep-disordered breathing promotes progression of pediatric NAFLD to NASH

Sleep-disordered breathing promotes progression of pediatric NAFLD to NASH

Studies have shown that obstructive sleep apnea and low nighttime oxygen, which result in oxidative stress, are associated with the progression of non-alcoholic fatty liver disease (NAFLD) in adults. [More]
New report urges all European countries to adopt universal vaccination for hepatitis

New report urges all European countries to adopt universal vaccination for hepatitis

To coincide with World Hepatitis Day, a new report, commissioned by United European Gastroenterology, calls for all European countries to adopt universal vaccination and harmonised screening programmes for hepatitis, as well as improved neonatal screening, to help speed up the eradication of the disease. [More]
New screen-and-treat programme for hepatitis B may thwart deadly complications of disease

New screen-and-treat programme for hepatitis B may thwart deadly complications of disease

Research into Africa's first 'screen-and-treat' programme for hepatitis B suggests the initiative may reduce deadly complications of the virus. [More]
Scientists discover promising approach to combat life-threatening bacterial infections without antibiotics

Scientists discover promising approach to combat life-threatening bacterial infections without antibiotics

Patients suffering from liver cirrhosis often die of life-threatening bacterial infections. In these patients the immune cells are unable to eliminate the bacterial infections. [More]
Researchers examine prevalence of CLD among ethnic minority populations in the U.S.

Researchers examine prevalence of CLD among ethnic minority populations in the U.S.

Chronic liver disease (CLD) and cirrhosis are serious liver conditions but little is known about how they affect ethnic minority populations in the United States. [More]
Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Health care resource use and costs of H.P. Acthar® gel for multiple sclerosis relapse

Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced new retrospective health economic data on H.P. Acthar® Gel (repository corticotropin injection; RCI), which may be an option for the management of multiple sclerosis (MS) relapses. [More]
FIB-4 index predicts HBV-related HCC

FIB-4 index predicts HBV-related HCC

Japanese researchers reveal an association between elevated FIB-4 index 24 weeks after the initiation of nucleos(t)ide analogue therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. [More]
Targeted molecular therapy reduces initial development of NAFLD in mice

Targeted molecular therapy reduces initial development of NAFLD in mice

Researchers report in the journal Cell Reports a targeted molecular therapy that dramatically reduces the initial development of Non Alcoholic Fatty Liver Disease (NAFLD) in laboratory mouse models of the disease. [More]
Researchers develop in vitro model system for investigating etiology of NAFLD

Researchers develop in vitro model system for investigating etiology of NAFLD

Researchers from the Institute for Stem Cell Research and Regenerative Medicine at the University Clinic of Düsseldorf have established an in vitro model system for investigating nonalcoholic fatty liver disease (NAFLD). [More]
Epclusa drug receives FDA approval for treating adult patients with chronic HCV

Epclusa drug receives FDA approval for treating adult patients with chronic HCV

The U.S. Food and Drug Administration approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis (advanced liver disease). [More]
Scientists discover link between two genes involved in PD and autoimmune diseases

Scientists discover link between two genes involved in PD and autoimmune diseases

A study publish in the journal CELL indicates that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease. [More]
HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

HCC predictors identified for chronic HBV patients with newly diagnosed cirrhosis

In patients with chronic hepatitis B virus infection who have been newly diagnosed with cirrhosis, the risk of hepatocellular carcinoma development can be ascertained using several clinical and molecular factors, study findings indicate. [More]
Clinical trial finds pioglitazone drug safe and effective for NASH patients

Clinical trial finds pioglitazone drug safe and effective for NASH patients

Researchers have found that an existing diabetes drug can be used to halt progression of another disease that is a leading cause of liver transplants. [More]
New studies provide future treatment strategies for stomach ulcers, IBD and alcoholic liver disease

New studies provide future treatment strategies for stomach ulcers, IBD and alcoholic liver disease

Basic and translational research paves the way for breakthroughs that can ultimately change patient care. [More]
Portal vein hypertension diminishes after hepatitis C recovery

Portal vein hypertension diminishes after hepatitis C recovery

This inflammatory viral infection of the liver causes inflexible scar tissue to form. This in turn impedes blood flow through the organ, with resulting hypertension in the portal vein. [More]
New RNA aptamer can prevent pathogenic protein misfolding

New RNA aptamer can prevent pathogenic protein misfolding

Several diseases occur when mutations cause misfolding of proteins. These include "serpinopathies" which is a group of rare heritable diseases. They are caused by mutations of so-called "serpin" inhibitors of proteolytic enzymes involved in blood coagulation, tissue remodeling, and other important physiological functions. [More]

Novel enzyme immunoassay helps diagnose HCV infection in one simple step

The current standard in diagnosing Hepatitis C virus (HCV) infection requires two sequential steps that make it suboptimal, costly, inconvenient, time consuming, and globally not widely available or affordable. [More]
Advertisement